Papers reviewed not cited A-G

  1. Aaron SD, Ramsay T, Vandemheen K, Whitmore GA. A threshold regression model for recurrent exacerbations in chronic obstructive pulmonary disease. J Clin Epidemiol. 2010 Dec;63(12):1324-31
  2. Aaron SD, Vandemheen KL, Maltais F, Field SK, Sin DD, Bourbeau J, Marciniuk DD, FitzGerald JM, Nair P, Mallick R. TNFα antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial. Thorax. 2013 Feb;68(2):142-8. doi: 10.1136/thoraxjnl-2012-202432.
  3. Abrams TE, Vaughan-Sarrazin M, Fan VS, Kaboli PJ Geographic Isolation and the Risk for Chronic Obstructive Pulmonary Disease–Related Mortality: A Cohort Study. Ann Intern Med. 2011;155:80-86
  4. Ackermann E. Barriers to Appropriate Care in General Practice MJA 197(2) 16 July 2012: 76-77.
  5. Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials. Chest. 2010 Feb;137(2):318-25
  6. Aggarwal AN, Gupta D, Agarwal R, Jindal SK. Comparison of the lower confidence limit to the fixed-percentage method for assessing airway obstruction in routine clinical practice. Respir Care. 2011 Nov;56(11):1778-84
  7. Agusti A, Edwards LD, Celli B, Macnee W, Calverley PM, Müllerova H, Lomas DA, Wouters E, Bakke P, Rennard S, Crim C, Miller BE, Coxson HO, Yates JC, Tal-Singer R, Vestbo J; ECLIPSE Investigators. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J. 2013 Sep;42(3):636-46.
  8. Agusti A, Hurd S, Jones P, Fabbri LM, Martinez F, Vogelmeier C, Vestbo J, Rodriguez-Roisin R. FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. Eur Respir J. 2013 Nov;42(5):1391-401.
  9. Agusti A, MacNee W. The COPD control panel: towards personalised Thorax 2013;68:687–690.
  10. Ahmadi Z, Bornefalk-Hermansson A, Franklin KA, Midgren B, Ekström MP. Hypo- and hypercapnia predict mortality in oxygen-dependent chronic obstructive pulmonary disease: a population-based prospective study. Respir Res. 2014;15:30.
  11. AIHW. Mortality from Asthma and COPD in Australia. Australian Institute of Health and Welfare, Poulos LM, Cooper SJ, Ampon R, Reddel HK and Marks GB 2014. Mortality from asthma and COPD in Australia. 30.Canberra: AIHW
  12. Al Zaabi A, Asad F, Abdou J, Al Musaabi H, Al Saiari MB, Buhussien AS, Nagelkerke N, Soriano JB. Prevalence of COPD in Abu Dhabi, United Arab Emirates. Respir Med. 2011 Apr;105(4):566-70.
  13. Albers M, Schermer T, Heijdra Y, Molema J, Akkermans R, van Weel C. Predictive value of lung function below the normal range and respiratory symptoms for progression of chronic obstructive pulmonary disease. Thorax. 2008 Mar;63(3):201-7. Epub 2007 Sep 28
  14. Albert P, Agusti A, Edwards L, Tal-Singer R, Yates J, Bakke P, Celli BR, Coxson HO, Crim C, Lomas DA, Macnee W, Miller B, Rennard S, Silverman EK, Vestbo J, Wouters E, Calverley P. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax. 2012 Aug;67(8):701-8. Epub 2012 Jun 13.
  15. Alfageme I, Vazquez R, Reyes N, Munoz J, Fernandez A, Hernandez M, Merino M, Perez J, Lima J. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006;61:189–195
  16. Allegra L, Grassi C et al. Ruolo degli antibiotici nel trattamento delle riacutizzazioni della bronchite cronica: risultati di uno studio italiano multicentrico. Ital J Chest Dis 1991;45:138-148
  17. Andersen ZJ, Hvidberg M, Jensen SS, Ketzel M, Loft S, Sørensen M, Tjønneland A, Overvad K, Raaschou-Nielsen O. Chronic obstructive pulmonary disease and long-term exposure to traffic-related air pollution: a cohort study.  Am J Respir Crit Care Med. 2011 Feb 15;183(4):455-61
  18. Andrews R, Lynch M. Heliox in the treatment of chronic obstructive pulmonary disease. Emergency Medicine Journal 2004; 21(6): 670-675
  19. Argula RG, Strange C, Ramakrishnan V, Goldin J. Baseline Regional Perfusion Impacts Exercise Response to Endobronchial Valve Therapy in Advanced Pulmonary Emphysema. Chest 2013;144(5):1578–1586
  20. Ashworth NL, Chad KE, Harrison EL, Reeder BA, Marshall SC. Home versus center based activity programs in older adults. The Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No.: CD004017.pub2. DOI: 10.1002/14651858:CD004017.pub2
  21. Atkinson RW, Carey IM, Kent AJ, van Staa TP, Anderson HR, Cook DG. Long-term exposure to outdoor air pollution and the incidence of chronic obstructive pulmonary disease in a national English cohort. Occup Environ Med. 2015 Jan;72(1):42-8.
  22. Au DH, Udris EM, Engelberg RA, Diehr PH, Bryson CL, Reinke LF, Curtis JR. A randomized trial to improve communication about end-of-life care among patients with COPD. Chest 2012; 141(3):726–735
  23. Austin M, Wood-Baker R. Oxygen therapy in the pre-hospital setting for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 3 John Wiley & Sons, Ltd Chichester UK DOI: 10.1002/14651858.CD005534.pub2
  24. Austin M, Wood-Baker R,  Oxygen therapy in the pre-hospital setting for people suffering from an acute exacerbation of chronic obstructive pulmonary disease.  The Cochrane Database of Systematic Reviews: Protocols 2005 Issue 4. John Wiley & Sons, Ltd Chichester, UK DOI: 10.1002/14651858.CD005534
  25. Bahadori K, FitzGerald JM. Risk factors of hospitalization and readmission of patients with COPD exacerbation–systematic review. Int J Chron Obstruct Pulmon Dis. 2007;2(3):241-51
  26. Baker WL, Baker EL, Coleman CI. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.  Pharmacotherapy. 2009 Aug;29(8):891-905
  27. Balasubramanian V, Naing S. Hypogonadism in chronic obstructive pulmonary disease: incidence and effects. Curr Opin Pulm Med. 2012 Mar;18(2):112-7
  28. Barnes PJ, Pocock SJ, Magnussen H, Iqbal A, Kramer B, Higgins M, Lawrence D. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther. 2010 Jun;23(3):165-71
  29. Bartolomeo N, Trerotoli P, Moretti A, Serio G. A Markov model to evaluate hospital readmission. BMC Medical Research Methodology 2008, 8:23 doi:10.1186/1471-2288-8-23 (provisional Pdf)
  30. Baselli LM, Oswald MA, Nashelsky JM.  Clinical inquiries. Do beta-blockers worsen respiratory status for patients with COPD?  J Fam Pract 2005 May;54(5): 472-3
  31. Bastin AJ, Starling L, Ahmed R, Dinham A, Hill N, Stern M, Restrick LJ. High prevalence of undiagnosed and severe chronic obstructive pulmonary disease at first hospital admission with acute exacerbation. Chronic Respiratory Disease 2010; 7(2) 91–97
  32. Bateman E, Singh D, Smith D, Disse B, Towse L, Massey D, Blatchford J, Pavia D, Hodder R. Efficacy and safety of tiotropium Respimat® SMI in COPD in two 1-year randomized studies. International Journal of COPD 2010:5 197–20
  33. Battaglia E, Fulgenzi A, Ferrero ME. Rationale of the combined use of inspiratory and expiratory devices in improving maximal inspiratory pressure and maximal expiratory pressure of patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2009 Jun;90(6):913-8
  34. Bautista J, Ehsan M, Normandin E, ZuWallack R, Lahiri B. Physiologic responses during the six minute walk test in obese and non-obese COPD patients. Respiratory Medicine 2011;105:1189-1194
  35. Beauchamp MK, Janaudis-Ferreira T, Parreira V, Romano JM, Woon L, Goldstein RS, Brooks D. A randomized controlled trial of balance training during pulmonary rehabilitation for individuals with COPD. Chest. 2013 Dec;144(6):1803-10. doi: 10.1378/chest.13-1093.
  36. Beauchamp MK, Nonoyama M, Goldstein RS, Hill K, Dolmage TE, Mathur S, Brooks D. Interval versus continuous training in individuals with chronic obstructive pulmonary disease-a systematic review. Thorax. 2010 Feb;65(2):157-64
  37. Bednarek M, Gorecka D, Wielgomas J, Czajkowska-Malinowska M, Regula J, Mieszko-Filipczyk G, Jasionowicz M, Bijata-Bronisz R, Lempicka-Jastrzebska M, Czajkowski M, Przybylski G, Zielinski J. Smokers with airway obstruction are more likely to quit smoking. Thorax 2006;61:869-873
  38. Beeh KM, Kornmann O, Beier J, Ksoll, M, Buhl R. Clinical application of a simple questionnaire for the differentiation of asthma and chronic obstructive pulmonary disease. Respiratory Medicine 2004;98:591-7
  39. Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. International Journal of COPD 2012:7 503–513
  40. Beier J, Beeh KM, Brookman L, Peachey G, Hmissi A, Pascoe S. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther. 2009 Dec;22(6):492-6
  41. Berton DC, Reis M, Siqueira AC, Barroco AC, Takara LS, Bravo DM, Andreoni S, Neder JA. Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD. Respir Med. 2010 Sep;104(9):1288-96.
  42. Bize R, Burnand B, Mueller Y, Cornuz J. Effectiveness of biomedical risk assessment as an aid for smoking cessation: a systematic review. Tob Control. 2007 Jun;16(3):151-6
  43. Bjoernshave B, Korsgaard J, Nielsen CV. Does pulmonary rehabilitation work in clinical practice? A review on selection and dropout in randomized controlled trials on pulmonary rehabilitation. Clinical Epidemiology 2010:2 73–83
  44. Bjørgen S, Hoff J, Husby VS, Høydal MA, Tjønna AE, Steinshamn S, Richardson RS, Helgerud J. Aerobic high intensity one and two legs interval cycling in chronic obstructive pulmonary disease: the sum of the parts is greater than the whole. Eur J Appl Physiol 2009;106:501–507
  45. Blanc PD. Occupation and COPD: a brief review. J Asthma. 2012 Feb;49(1):2-4
  46. Blasi F, Bonardi D, Aliberti S, Tarsia P, Confalonieri M, Amir O, Carone M, Di Marco F, Centanni S, Guffanti E. Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulm Pharmacol Ther. 2010 Jun;23(3):200-7
  47. Blumenthal JA, Emery CF, Smith PJ, Keefe FJ, Welty-Wolf K, Mabe S, Martinu T, Johnson JJ, Babyak MA, O’Hayer VF, Diaz PT, Durheim M, Baucom D, Palmer SM. The effects of a telehealth coping skills intervention on outcomes in chronic obstructive pulmonary disease: primary results from the INSPIRE-II study. Psychosom Med. 2014 Oct;76(8):581-92.
  48. Bollmeier SG, Prosser TR. Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease. Ann Pharmacother. 2014 Feb;48(2):250-7.
  49. Bon J, Liao S, Tseng G, Sciurba FC. Considerations and pitfalls in phenotyping and reclassification of chronic obstructive pulmonary disease. Translational Research 2013;162:252–257.
  50. Booker R. Chronic obstructive pulmonary disease and the NICE guideline. Nurs Stand. 2005 Feb 9-15;19(22): 43-52
  51. Bor S, Kitapcioglu G, Solak ZA, Ertilav M, Erdinc M. Prevalence of gastroesophageal reflux disease in patients with asthma and chronic obstructive pulmonary disease. J Gastroenterol Hepatol. 2010 Feb;25(2):309-13
  52. Borges RC, Carvalho CR. Impact of resistance training in chronic obstructive pulmonary disease patients during periods of acute exacerbation. Arch Phys Med Rehabil. 2014 Sep;95(9):1638-45.
  53. Borrill ZL, Houghton CM, Tal-Singer R, Vessey SR, Faiferman I, Langley SJ, Singh D. The use of plethysmography and oscillometry to compare long-acting bronchodilators in patients with COPD. Br J Clin Pharmacol. 2008 Feb;65(2):244-52
  54. Bourbeau J. Disease-specific self-management programs in patients with advanced chronic obstructive pulmonary disease: a comprehensive and critical evaluation. Disease Management and Health Outcomes 2003;11(5):311-319
  55. Bourbeau J, Collet JP, Schwartzman K, Ducruet T, Nault D, Bradley C. Economic benefits of self-management education in COPD. Chest. 2006 Dec;130(6):1704-11
  56. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008 Sep;63(9):831-8
  57. Bourbeau J, Saad N. Integrated care model with self-management in chronic obstructive pulmonary disease: from family physicians to specialists. Chron Respir Dis. 2013 May;10(2):99-105. doi: 10.1177/1479972312473844. Epub 2013 Feb 4.
  58. Bourdin A, Serre I, Flamme H, Vic P, Neveu D, Aubas P, Godard P, Chanez P. Can endobronchial biopsy analysis be recommended to discriminate between asthma and COPD in routine practice? Thorax 2004;59:488-493
  59. Bratås O, Espnes GA, Rannestad T, Walstad R. Characteristics of patients with chronic obstructive pulmonary disease choosing rehabilitation. J Rehabil Med. 2010 Apr;42(4):362-7
  60. Bridevaux PO, Gerbase MW, Probst-Hensch NM, Schindler C, Gaspoz JM, Rochat T. Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax. 2008 Sep;63(9):768-74
  61. British Thoracic Society Guideline. Intermediate-care: Hospital-at-Home in chronic obstructive pulmonary disease. Thorax 2007;62(3):200-210
  62. Brito-Mutunayagam R, Appleton SL, Wilson DH, Ruffin RE, Adams RJ; North West Adelaide Cohort Health Study Team. Global Initiative for Chronic Obstructive Lung Disease stage 0 is associated with excess FEV1 decline in a representative population sample. Chest. 2010 Sep;138(3):605-13.
  63. Brown, CD, McCrory D, White J. Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews: Reviews 2001 Issue 1 John Wiley & Sons, Ltd Chichester, UK DOI: 10.1002/14651858.CD002984
  64. Brown CD, Fessler HE. Lung volume reduction surgery. COPD 2005;2(3):363-75
  65. Brown CD, McCrory D, White J. Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews 2001, Issue 1. Art. No.: CD002984. DOI: 10.1002/14651858:CD002984
  66. Brutsche MH, Grossman P, Müller RE, Wiegand J, Pello, Baty F, Ruch W. Impact of laughter on air trapping in severe chronic obstructive lung disease. Int J Chron Obstruct Pulmon Dis. 2008;3(1):185-92
  67. Buhl R, Banerji D. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. International Journal of COPD 2012:7 729–741
  68. Bulley C, Donaghy M, Howden S, Salisbury L, Whiteford S, Mackay E. A prospective qualitative exploration of views about attending pulmonary rehabilitation. Physiother Res Int 2009;14(3):181–192
  69. Busby AK, Reese RL, Simon SR. Pulmonary rehabilitation maintenance interventions: a systematic review. Am J Health Behav. 2014 May;38(3):321-30.
  70. Calbo E, Valdés E, Ochoa de Echagüen A, Fleites A, Molinos L, Xercavins M, Freixas N, Rodríguez-Carballeira M, Garau J. Bacteraemic pneumococcal pneumonia in COPD patients: better outcomes than expected. Eur J Clin Microbiol Infect Dis. 2009 Aug;28(8):971-6
  71. Calderón-Larrañaga A, Carney L, Soljak M, Bottle A, Partridge M, Bell D, Abi-Aad G, Aylin P, Majeed A. Association of population and primary healthcare factors with hospital admission rates for chronic obstructive pulmonary disease in England: national cross-sectional study. Thorax. 2011 Mar;66(3):191-6
  72. Calverley PMA, Kuna P, Monso E, Costantini M, Petruzzelli S, Sergio F, Varoli G, Papi A, Brusasco V. Beclomethasone/formoterol in the management of COPD: A randomised controlled trial. Respiratory Medicine 2010;104: 1858-1868
  73. Camillo CA, de Moraes Laburu V, Soriano, Goncalves NS, Cavalheri V, Tomasi FP, Hernandes NA, Ramos D, Vanderlei LCM, Ramos EMC, Probst VS, Pitta F. Improvement of heart rate variability after exercise training and its predictors in COPD. Respiratory Medicine (2011) 105, 1054-1062
  74. Carolan BJ, Sutherland ER. Clinical phenotypes of chronic obstructive pulmonary disease and asthma: recent advances. J Allergy Clin Immunol. 2013 Mar;131(3):627-34; quiz 635. doi: 10.1016/j.jaci.2013.01.010. Epub 2013 Jan 26
  75. Carron M, Freo U, BaHammam AS, Dellweg D, Guarracino F, Cosentini R, Feltracco P, Vianello A, Ori C, Esquinas A. Complications of non-invasive ventilation techniques: a comprehensive qualitative review of randomized trials. Br J Anaesth. 2013 Jun;110(6):896-914. doi: 10.1093/bja/aet070.
  76. Casanova C, Cote C, Marin JM, Pinto-Plata V, de Torres JP, Aguirre-Jaíme A, Vassaux C, Celli BR. Distance and oxygen desaturation during the 6-min walk test as predictors of long-term mortality in patients with COPD. Chest. 2008 Oct;134(4):746-52
  77. Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD006363. DOI: 10.1002/14651858.CD006363.pub2
  78. Cazzola M, Ando F, Santus P, Rugger P, Di Marco F, Sanduzzi A, D’Amato M. A pilot study to assess the effects of combining fluticasone propionate/ salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD Pulmonary Pharmacology & Therapeutics 20 (2007) 556–561
  79. Cazzola M, Santus P, D’Adda A, Pizzolato S, Di Marco F, Centanni S. Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPD. Pulm Pharmacol Ther. 2009 Jun;22(3):177-82
  80. Cazzola M, Santus P, Di Marco F, Boveri B, Castagna F, Carlucci P, Matera MG, Centanni S. Bronchodilator effect of an inhaled combination therapy with salmeterol & fluticasone and formoterol & budesonide in patients with COPD. 2003;97:453-7
  81. Cazzola M, Santus P, Di Marco F, Carlucci P, Mondoni M, Matera MG, Centanni S. Onset of action of formoterol/ budesonide in single inhaler vs. formoterol in patients with COPD. 2004;17:121-125
  82. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovascular Safety of Tiotropium in Patients with COPD. Chest 2010;137;20-30
  83. Chorão P, Pereira AM, Fonseca JA. Inhaler devices in asthma and COPD–an assessment of inhaler technique and patient preferences. Respir Med. 2014 Jul;108(7):968-75
  84. Chatterjee AB, Rissmiller RW, Meade K, Paladenech C, Conforti J, Adair NE, Haponik EF, Chin R. Reproducibility of the 6-Minute Walk Test for Ambulatory Oxygen Prescription. Respiration 2010;79:121–127
  85. Chen CZ, Ou CY, Wang WL, Lee CH, Lin CC, Chang HY, et al. Using post-bronchodilator FEV₁ is better than pre-bronchodilator FEV₁ in evaluation of COPD severity. COPD. 2012;9(3):276-80
  86. Chhabra SK, Vijayan VK, Vasu T. Inhaled formoterol versus ipratropium bromide in chronic obstructive pulmonary disease. Indian J Chest Dis Allied Sci 2006;48(2):97-102
  87. Chiappa GR, Queiroga F Jr, Meda E, Ferreira LF, Diefenthaeler F, Nunes M, Vaz MA, Machado MC, Nery LE, Neder JA. Heliox improves oxygen delivery and utilization during dynamic exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009 Jun 1;179(11):1004-10
  88. Chin RC, Guenette JA, Cheng S, Raghavan N, Amornputtisathaporn N, Cortés-Télles A, Webb KA, O’Donnell DE. Does the respiratory system limit exercise in mild chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 2013 Jun 15;187(12):1315-23. doi: 10.1164/rccm.201211-1970OC.
  89. Chittleborough CR, Burke MJ, Taylor AW, Wilson DH, Phillips PJ, Adams RJ, Ruffin RE; North West Adelaide Health Study Team. Medicare-related service use and costs among people with diagnosed and undiagnosed diabetes and respiratory conditions. Aust Health Rev. 2009 Feb;33(1):107-16
  90. Chuang ML, Lin IF, Vintch JR, Tien EH. Using statistical techniques to predict dynamic arterial pCO2 in patients with COPD during maximum exercise. Respir Care. 2012 Jul;57(7):1106-14
  91. Cirio S, Nava S. Pilot study of a new device to titrate oxygen flow in hypoxic patients on long-term oxygen therapy. Respir Care. 2011 Apr;56(4):429-34.
  92. Choudhury AB, Dawson CM, Kilvington HE, Eldridge S, James W-Y, Wedzicha JA, Feder GS, Griffiths CJ. Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial Respiratory Research 2007 8:93
  93. Church A, Beerahee M1, Brooks J, Mehta R, Shah P. Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study. BMC Pulmonary Medicine 2014, 14:2 BMC Pulm Med. 2014 Jan 6;14:2.
  94. Coin A, Sergi G, Marin S, Vianello A, Perissinotto E, Sarti S, Rinaldi G, Mosele M, Inelmen EM, Enzi G, Manzato E. Predictors of low bone mineral density in elderly males with chronic obstructive pulmonary disease: the role of body mass index. Aging Male. 2010 Jun;13(2):142-7
  95. Colebourn CL, Barber V, Young JD. Use of helium-oxygen mixture in adult patients presenting with exacerbations of asthma and chronic obstructive pulmonary disease: a systematic review. Anaesthesia 2007;62(1):34-42
  96. Contoli M, Baraldo S, Marku B, Casolari P, Marwick JA, Turato G, Romagnoli M, Caramori G, Saetta M, Fabbri LM, Papi A. Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up. J Allergy Clin Immunol. 2010 Apr;125(4):830-7
  97. Cooper CB & Tashkin DP. Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease. BMJ 2005; 330: 640-4
  98. Cope S, Capkun‐Niggli G, Gale R, Jardim JR, Jansen JP. Comparative efficacy of indacaterol 150 mug and 300 mug versus fixed‐dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease: a network meta‐analysis. International Journal of Chronic Obstructive Pulmonary Disease.2011;6:329‐344
  99. Cope S, Capkun-Niggli G, Gale R, Lassen C, Owen R, Ouwens MJ, Bergman G, Jansen JP. Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison. Value Health. 2012 May;15(3):524-33
  100. Cope S, Donohue JF, Jansen JP, Kraemer M, Capkun-Niggli G, Baldwin M, Buckley F, Ellis A, Jones P. Comparative efficacy of long-acting bronchodilators for COPD – a network meta-analysis. Respir Res. 2013 Oct 7;14(1):100.
  101. Corrao G et al. Short-acting inhaled beta-2-agonists increased the mortality from chronic obstructive pulmonary disease in observational designs. J Clin Epidemiol. 2005 Jan;58(1):92-7
  102. Costi S, Di Bari M, Pillastrini P, D’Amico R, Crisafulli E, Arletti C, Fabbri LM, Clini EM. Short-term efficacy of upper-extremity exercise training in patients with chronic airway obstruction: a systematic review. Phys Ther. 2009 May;89(5):443-55
  103. Coventry, A., Gemmell, I. & Todd, C. Psychosocial risk factors for hospital readmission in COPD patients on early discharge services: a cohort study. BMC Pulmonary Medicine, 11(49)
  104. Crawford GB, Brooksbank MA, Brown M, Burgess TA, Young M. Unmet needs of people with end-stage chronic obstructive pulmonary disease: recommendations for change in Australia. Internal Medicine Journal. Received 3 December 2011; accepted 5 March 2012.
  105. Crim C, Celli B, Edwards LD, Wouters E, Coxson HO, Tal-Singer R, Calverley PMA on behalf of the ECLIPSE investigators. Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results.  Respiratory Medicine (2011) 105, 1069-1078
  106. Dalal AA, St Charles M, Petersen HV, Roberts MH, Blanchette CM, Manavi-Zieverink K. Cost-effectiveness of combination fluticasone propionate–salmeterol 250/50μg versus salmeterol in severe COPD patients. International Journal of Chronic Obstructive Pulmonary Disease 2010:5 179–187
  107. Daubin C et al. Procalcitonin levels in acute exacerbation of COPD admitted in ICU: a prospective cohort study BMC Infectious Diseases 2008, 8:145
  108. De Coster DA, Jones M, Thakrar N. Beclometasone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD009769. DOI: 10.1002/14651858.CD009769.pub2.
  109. de Marco R, Accordini S, Antò JM, Gislason T, Heinrich J, Janson C, Jarvis D, Künzli N, Leynaert B, Marcon A, Sunyer J, Svanes C, Wjst M, Burney P. Long-term outcomes in mild/moderate chronic obstructive pulmonary disease in the European community respiratory health survey. Am J Respir Crit Care Med. 2009 Nov 15;180(10):956-63
  110. de Sousa Pinto JM, Martín-Nogueras AM, Calvo-Arenillas JI, Ramos-González J. Clinical benefits of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil Prev. 2014 Sep-Oct;34(5):355-9.
  111. de Torres JP, Casanova C, Hernandez C, Abreu J, Montejo de Garcini A, Aguirre-Jaime A, Celli BR. Gender associated differences in determinants of quality of life in patients with COPD: a case series study. Health and Quality of Life Outcomes 2006;4:72
  112. de-Torres JP, Wilson DO, Sanchez-Salcedo P, Weissfeld JL, Berto J, Campo A, Alcaide AB, García-Granero M, Celli BR, Zulueta JJ. Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. Am J Respir Crit Care Med. 2015 Feb 1;191(3):285-91.
  113. de Torres JP, Casanova C, Marín JM, Pinto-Plata V, Divo M, Zulueta JJ, Berto J, Zagaceta J, Sanchez-Salcedo P, Cabrera C, Carrizo S, Cote C, Celli BR. Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE. Thorax. 2014 Sep;69(9):799-804.
  114. Deacon SJ, Vincent EE, Greenhaff PL, Fox J, Steiner MC, Singh SJ, Morgan MD. Randomized controlled trial of dietary creatine as an adjunct therapy to physical training in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008 Aug 1;178(3):233-9
  115. Decramer, Marc and Ferguson, Gary. Clinical Safety of Long-Acting â2-Agonist and Inhaled Corticosteroid Combination Therapy in COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease,2006 3:3, 163–171
  116. Decramer M, Dahl R, Kornmann O, Korn S, Lawrence D, McBryan D. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use. Respir Med. 2013 Feb;107(2):223-32.
  117. Decramer M, Rossi A, Lawrence D, McBryan D. Indacaterol therapy in patients with COPD not receiving other maintenance treatment. Respir Med. 2012 Dec;106(12):1706-14. doi: 10.1016/j.rmed.2012.08.022. Epub 2012 Sep 29.
  118. Delfino RJ, Brummel S, Wu J, Stern H, Ostro B, Lipsett M, Winer A, Street DH, Zhang L, Tjoa T, Gillen DL. The relationship of respiratory and cardiovascular hospital admissions to the southern California wildfires of 2003. Occup Environ Med. 2009 Mar;66(3):189-97
  119. Dennis SM, Harris M, Lloyd J, Powell Davies G, Faruqi N, Zwar N. Do people with existing chronic conditions benefit from telephone coaching? A rapid review. Australian Health Review, 2013;37:381–388.
  120. Desveaux L, Beauchamp M, Goldstein R, Brooks D. Community-based Exercise Programs as a Strategy to Optimize Function in Chronic Disease -A Systematic Review. Med Care. 2014 Mar;52(3):216-26.
  121. Devine EC, Pearcy J. Meta-analysis of the effects of psychoeducational care in adults with chronic obstructive pulmonary disease. Patient Education & Counseling. 1996;29(2):167-78
  122. Di Meo F, Pedone C, Lubich S, Pizzoli C, Traballesi M, Incalzi RA. Age does not hamper the response to pulmonary rehabilitation of COPD patients. Age Ageing. 2008 Sep;37(5):530-5
  123. Diahn-Warng Perng,Cheng-Che WU, Kang-Cheng Su, Yu-Chin Lee, Reury-Perng Perng, Chi-Wei Tao. Additive benefits of tiotropium in COPD patients treated with long-acting b2 agonists and corticosteroids. Respirology (2006) 11, 598–602
  124. Dimopoulos G, Siempo II, Korbila IP, Manta KG, Falagas ME. Comparison of First-Line With Second-Line Antibiotics for Acute Exacerbations of Chronic Bronchitis: A Metaanalysis of Randomized Controlled Trials. Chest 2007; 132:447–455
  125. Ding M, Zhang W, Li K, Chen X. Effectiveness of T’ai Chi and Qigong on Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. J Altern Complement Med. 2013 Aug 20. [Epub ahead of print]
  126. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, Zulueta J, Cabrera C, Zagaceta J, Hunninghake G, Celli B; BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012 Jul 15;186(2):155-61. Epub 2012 May 3.
  127. Dolmage TE and Goldstein RS. Effects of One-Legged Exercise Training of Patients With COPD Chest 2008; 133:370–376
  128. Dolmage TE, Evans RA, Hill K, Blouin M, Brooks D, Goldstein RS. The effect of pulmonary rehabilitation on critical walk speed in patients with COPD: a comparison with self-paced walks. Chest. 2012 Feb;141(2):413-9
  129. Dolmage TE, Janaudis-Ferreira T, Hill K, Price S, Brooks D, Goldstein RS. Arm elevation and coordinated breathing strategies in patients with COPD. Chest. 2013 Jul;144(1):128-35. doi: 10.1378/chest.12-2467.
  130. Donaldson GC, Müllerova H, Locantore N, Hurst JR, Calverley PM, Vestbo J, Anzueto A, Wedzicha JA. Factors associated with change in exacerbation frequency in COPD. Respir Res. 2013 Jul 30;14:79. doi: 10.1186/1465-9921-14-79.
  131. Donohue JF, Anzuetob A, Brooks J, Mehtad R, Kalberg C, Crater G. A randomized, double-blind dose-ranging studyof the novel LAMA GSK573719 in patients with COPD. Resp Med 2012;106:970-979.
  132. Dransfield MT, Nahm MH, Han MK, Harnden S, Criner GJ, Martinez FJ, Scanlon PD, Woodruff PG, Washko GR, Connett JE, Anthonisen NR, Bailey WC; COPD Clinical Research Network. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009 Sep 15;180(6):499-505
  133. Dreher M, Storre JH, Schmoor C, Windisch W. High-intensity versus low-intensity non-invasive ventilation in patients with stable hypercapnic COPD: a randomised crossover trial. Thorax. 2010 Apr;65(4):303-8
  134. Drexel C, Jacobson A, Hanania NA, Whitfield B, Katz J, Sullivan T. Measuring the impact of a live, case-based, multiformat, interactive continuing medical education program on improving clinician knowledge and competency in evidence-based COPD care. International Journal of COPD 2011:6 297–307
  135. Drummond MB, Blackford AL, Benditt JO, Make BJ, Sciurba FC, McCormack MC, Martinez FJ, Fessler HE, Fishman AP, Wise RA; NETT Investigators. Continuous oxygen use in nonhypoxemic emphysema patients identifies a high-risk subset of patients: retrospective analysis of the National Emphysema Treatment Trial. Chest. 2008 Sep;134(3):497-506
  136. Duiverman ML, Wempe JB, Bladder G, Vonk JM, Zijlstra JG, Kerstjens HAM, Wijkstra PJ. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in COPD patients: A RCT. Respiratory Research 2011, 12:112
  137. Dummer JF, Epton MJ, Cowan JO, Cook JM, Condliffe R, Landhuis CE, Smith AD, Taylor DR. Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide. Am J Respir Crit Care Med. 2009 Nov 1;180(9):846-52
  138. Egan C, Deering BM, Blake C, Fullen BM, McCormack NM, Spruit MA, Costello RW. Short term and long term effects of pulmonary rehabilitation on physical activity in COPD. Respir Med. 2012 Dec;106(12):1671-9. doi: 10.1016/j.rmed.2012.08.016. Epub 2012 Oct 12.
  139. Eisner MD, Omachi TA, Katz PP, Yelin EH, Iribarren C, Blanc PD. Measurement of COPD severity using a survey-based score: validation in a clinically and physiologically characterized cohort. Chest. 2010 Apr;137(4):846-51
  140. Ernst A, Odell DD, Michaud G, Majid A, Herth FF, Gangadharan SP. Central airway stabilization for tracheobronchomalacia improves quality of life in patients with COPD. Chest. 2011 Nov;140(5):1162-8
  141. Esteban C, Arostegui I, Aburto M, Moraza J, Quintana JM, Aizpiri S, Basualdo LV, Capelastegui A. Influence of changes in physical activity on frequency of hospitalization in chronic obstructive pulmonary disease. Respirology. 2014 Apr;19(3):330-8
  142. Esteban C, Quintana JM, Moraza J, Aburto M, Aguirre U, Aguirregomoscorta JI, Aizpiri S, Basualdo LV, Capelastegui A. BODE-Index vs HADO-score in chronic obstructive pulmonary disease: Which one to use in general practice? BMC Med. 2010 May 24;8:28.
  143. Esteban A, Frutos-Vivar F, Ferguson ND, Arabi Y, Apezteguia C, Gonzalez M, Epstein SK, Hill NS, Nava S, Soares M-A, D’Empaire G, Alia I, Anzueto A. Noninvasive positive-pressure ventilation for respiratory failure after extubation. The New England Journal of Medicine 2004; 350: 2452-2460
  144. Evans J and Chen Y. The Association Between Home and Vehicle Environmental Tobacco Smoke (ETS) and Chronic Bronchitis in a Canadian Population: The Canadian Community Health Survey 2005 Inhalation Toxicology 2009;21:244–249
  145. Eves ND, Sandmeyer LC, Wong EY, Jones LW, MacDonald GF, Ford GT, Petersen SR, Bibeau MD, Jones RL. Helium-hyperoxia: a novel intervention to improve the benefits of pulmonary rehabilitation for patients with COPD. Chest. 2009 Mar;135(3):609-18
  146. Ferguson GT, Fležar M, Korn S, Korducki L, Grönke L, Abrahams R, Buhl R. Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis. Adv Ther. 2015 Jun;32(6):523-36.
  147. Ferré A, Fuhrman C, Zureik M, Chouaid C, Vergnenègre A, Huchon G, Delmas MC, Roche N. Chronic bronchitis in the general population: influence of age, gender and socio-economic conditions. Respir Med. 2012 Mar;106(3):467-71
  148. Ford PA, Durham AL, Russell RE, Gordon F, Adcock IM, Barnes PJ. Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest. 2010 Jun;137(6):1338-44
  149. Franciosi LG, Page CP, Celli BR, Cazzola M, Walker MJ, Danhof M, Rabe KF, Della Pasqua OE. Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2006;19(3):189-99
  150. Freeman D, Lee A, Price D. Efficacy and safety of tiotropium in COPD patients in primary care – the SPiRiva Usual CarE (SPRUCE) study. Respiratory Research 2007, 8:45
  151. Fridlender ZG, Arish N, Laxer U, Berkman N, Leibovitz A, Fink G, Breuer R. Randomized controlled crossover trial of a new oscillatory device as add-on therapy for COPD. COPD. 2012 Dec;9(6):603-10. doi: 10.3109/15412555.2012.748625. Epub 2012 Dec 6.
  152. Fuhr R, Magnussen H, Sarem K, Llovera AR, Kirsten AM, Falqués M, Caracta CF, Garcia Gil E. Efficacy of aclidinium bromide 400 μg twice daily compared with placeboand tiotropium in patients with moderate to severe COPD. Chest. 2012 Mar;141(3):745-52
  153. Gao Z, Liu Y, Zhang J. Effect of Jianpi therapy in treatment of COPD: a systematic review. Journal of Traditional Chinese Medicine 2013;33:1-8
  154. Gagnon P, Saey D, Provencher S, Milot J, Bourbeau J, Tan WC, Martel S, Maltais F. Walking exercise response to bronchodilation in mild COPD: a randomized trial. Respir Med. 2012 Dec;106(12):1695-705. doi: 10.1016/j.rmed.2012.08.021. Epub 2012 Sep 20.
  155. Gale NS, Duckers JM, Enright S, Cockcroft JR, Shale DJ, Bolton CE. Does Pulmonary Rehabilitation address Cardiovascular Risk Factors in Patients with COPD? BMC Pulmonary Medicine 2011, 11:20 doi:10.1186/1471-2466-11-20
  156. Gan WQ, Man SFP, Sin DD. Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulmonary Medicine 2005;5:3 doi:10.1186/1471-2466-5-3
  157. Garcia-Aymerich J, Gomez FP, Benet M, Farrero E, Basagan X, Gayete A, Pare C, Freixa X, Ferrer J, Ferrer A, Roca J, Galdiz JB, Sauleda J, Monso E, Gea J, Barbera JA, Agusti A, Anto JM, on behalf of the PAC-COPD Study Group. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax 2011;66:430-437. doi:10.1136/thx.2010.154484
  158. Garcia-Aymerich J, Serra Pons I, Mannino DM, Maas AK, Miller DP, Davis KJ. Lung function impairment, COPD hospitalisations and subsequent mortality. Thorax 2011;66:585-590
  159. Garcia-Talavera I, Tauroni A, Trujillo JL, Pitti R, Eiroa L, Aguirre-Jaime A, Sánchez A, Abreu J. Time to desaturation less than one minute predicts the need for long-term home oxygen therapy. Respir Care. 2011 Nov;56(11):1812-7
  160. Garrod R, Lasserson T. Role of physiotherapy in the management of chronic lung diseases: an overview of systematic reviews. Respir Med. 2007 Dec;101(12):2429-36. Epub 2007 Sep 17
  161. Gelb AF, Tashkin DP, Make BJ, Zhong X, Garcia Gil E, Caracta C, et al. Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD. Respir Med. 2013;107(12):1957-65.
  162. Gelb AF, Taylor CF, Cassino C, Shinar CM, Schein MJ, Zamel N. Tiotropium induced bronchodilation and protection from dynamic hyperinflation is independent of extent of emphysema in COPD. Pulm Pharmacol Ther. 2009 Jun;22(3):237-42
  163. Gellis ZD, Kenaley B, McGinty J, Bardelli E, Davitt J, Ten Have T. Outcomes of a telehealth intervention for homebound older adults with heart or chronic respiratory failure: a randomized controlled trial. Gerontologist. 2012 Aug;52(4):541-52. Epub 2012 Jan 11.
  164. Gershon AS, Warner L, Cascagnette P, Victor JC, To T. Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. Lancet 2011; 378: 991–96
  165. Gilbert A, Roughead E, Beilby J, Mott K, Barratt J. Collaborative medical management services: improving patient care. MJA 2002;177(4):189-192
  166. Global Initiative for Chronic Obstructive Lung Disease strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: an Asia-Pacific perspective. Respirology. 2005 Jan;10(1):9-17
  167. Gloeckl R, Heinzelmann I, Baeuerle S, Damm E, Schwedhelm A-L, Diril M, Buhrow D, Jerrentrup A, Kenn K. Effects of whole body vibration in patients with chronic obstructive pulmonary disease – A randomized controlled trial. Respiratory medicine 1 January 2012 (volume 106 issue 1 Pages 75-83 DOI: 10.1016/j.rmed.2011.10.021)
  168. Goossens LMA, Nivens MC, Sachs P, Monz BU, Rutten-van Molken MPMH. Is the EQ-5D responsive to recovery from a moderate COPD exacerbation? Respiratory Medicine (2011) 105, 1195-1202
  169. Gosker HR, Zeegers MP, Wouters EF, Schols AM. Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis. Thorax. 2007 Nov;62(11):944-9. Epub 2007 May 25
  170. Gotfried MH, Kerwin EM, Lawrence D, Lassen C, Kramer B. Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies. COPD. 2012 Dec;9(6):629-36. doi: 10.3109/15412555.2012.729623. Epub 2012 Sep 28.
  171. Govender N, Lalloo UG, Naidoo RN. Occupational exposures and chronic obstructive pulmonary disease: a hospital based case control study. Thorax 2011;66:597-601
  172. Graat-Verboom L, Smeenk FW, van den Borne BE, Spruit MA, Jansen FH, van Enschot JW, Wouters EF. Progression of osteoporosis in patients with COPD: a 3-year follow up study. Respir Med. 2012 Jun;106(6):861-70
  173. Greene CC, Bradley KA, Bryson CL, Blough DK, Evans LE, Udris EM, Au DH. The association between alcohol consumption and risk of COPD exacerbation in a veteran population. Chest. 2008 Oct;134(4):761-7
  174. Greening NJ, Williams JE, Hussain SF, Harvey-Dunstan TC, Bankart MJ, Chaplin EJ, et al. An early rehabilitation intervention to enhance recovery during hospital admission for an exacerbation of chronic respiratory disease: randomised controlled trial. BMJ. 2014;349:g4315
  175. Greenstone M & Lasserson TJ. Doxapram for ventilatory failure due to exacerbations of chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD000223. DOI: 10.1002/14651858:CD000223
  176. Greulich T, Kehr K, Nell C, Koepke J, Haid D, Koehler U, Koehler K, Filipovic S, Kenn K, Vogelmeier C, Koczulla AR. A randomized clinical trial to assess the influence of a three months training program (gym-based individualized vs. calisthenics-based non-invidualized) in COPD-patients. Respir Res. 2014 Mar 25;15:36. doi: 10.1186/1465-9921-15-36.
  177. Griffin J, Lee S, Caiado M, Kesten S, Price D. Comparison of tiotropium bromide and combined ipratropium/salbutamol for the treatment of COPD: a UK General Practice Research Database 12-month follow-up study. Prim Care Respir J. 2008 Jun;17(2):104-10
  178. Groenewegen KH, Postma DS, Hop WC, Wielders PL, Schlösser NJ, Wouters EF; COSMIC Study Group. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest. 2008 Feb;133(2):350-7. Epub 2008 Jan 15
  179. Guder G, Brenner S, Angermann CE, Ertl G, Held M, Sachs AP, Lammers J-W, Zanen P, Hoes AW,  Stork S, Rutten FH. GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study. Respiratory Research 2012, 13:13 doi:10.1186/1465-9921-13-13
  180. Gudmundsson G, Gislason T, Lindberg E, Hallin R, Ulrik CS, Brondum E, Nieminen MM, Aine T, Bakke P, Janson C. Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity. Respir Res 2006 Aug 16;7:109
  181. Guenette JA, Jensen D, Webb KA, Ofir D, Raghavan N, O’Donnell DE. Sex differences in exertional dyspnea in patients with mild COPD: Physiological Mechanisms. Respiratory Physiology & Neurobiology 2011;177:218–227
  182. Guenette JA, Raghavan N, Harris-McAllister V, Preston ME, Webb KA, O’Donnell DE. Effect of adjunct fluticasone propionate on airway physiology during rest and exercise in COPD. Respir Med. 2011 Dec;105(12):1836-45
    Gulbas G, Gunen H, In E, Kilic T. Long-term follow-up of chronic obstructive pulmonary disease patients on long-term oxygen treatment. Int J Clin Pract. 2012 Feb;66(2):152-7. doi: 10.1111/j.1742-1241.2011.02833.x
  183. Gulbas G, Gunen H, In E, Kilic T. Long-term follow-up of chronic obstructive pulmonary disease patients on long-term oxygen treatment. Int J Clin Pract. 2012 Feb;66(2):152-7. doi: 10.1111/j.1742-1241.2011.02833.x